Hepatic Interventional Oncology

2021 ◽  
pp. 415-441
Author(s):  
Seth I. Stein
2020 ◽  
Vol 37 (05) ◽  
pp. 484-491
Author(s):  
Cathal O'Leary ◽  
Michael C. Soulen ◽  
Susan Shamimi-Noori

AbstractMetastatic liver disease is one of the major causes of cancer-related morbidity and mortality. Locoregional therapies offered by interventional oncologists alleviate cancer-related morbidity and in some cases improve survival. Locoregional therapies are often palliative in nature but occasionally can be used with curative intent. This review will discuss important factors to consider prior to palliative and curative intent treatment of metastatic liver disease with locoregional therapy. These factors include those specific to the tumor, liver function, liver reserve, differences between treatment modalities, and patient-specific considerations.


2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Amgad M. Moussa ◽  
Etay Ziv

2021 ◽  
Vol 158 ◽  
pp. S213-S214
Author(s):  
C. Casà ◽  
R. Iezzi ◽  
F. Bruno ◽  
P. Cornacchione ◽  
M. Iezzi ◽  
...  

2017 ◽  
Vol 01 (03) ◽  
pp. 225-232
Author(s):  
Christopher Noda ◽  
Mihail Roubhaka ◽  
Resmi Charalel ◽  
Abdulrahman Masrani ◽  
Olaguoke Akinwande

AbstractMinimally invasive techniques in the treatment of cancer continue to develop at a rapid pace. Although surgical resection currently remains the only option for a complete cure, not all diseases are amenable to complete removal. This leaves opportunities to develop effective downstaging techniques as well as palliative care. In the realm of minimally invasive oncologic techniques, catheter-based therapies are an attractive option because malignancies require a blood supply to remain active. The intra-arterial (IA) delivery of specific tumoricidal drugs has been shown to be a successful delivery method in a variety of different cancers, and it is currently a progressive area of research. There is work both to increase the delivery specificity of oncologic drugs, including SW43 sigma receptor ligand and nanoparticle research. In addition, oncolytic viral therapy and 3-bromopyruvate have become increasingly more attractive tumoricidal drug prospects. In the future, the success of these therapies will ultimately determine the degree to which IA delivery will compete with the systemic delivery of drugs in the treatment of cancer.


Liver Cancer ◽  
2016 ◽  
Vol 6 (1) ◽  
pp. 34-43 ◽  
Author(s):  
Matteo Donadon ◽  
Luigi Solbiati ◽  
Laura Dawson ◽  
Aisling Barry ◽  
Gonzalo Sapisochin ◽  
...  

2019 ◽  
Vol 30 (1) ◽  
pp. 38-41.e1 ◽  
Author(s):  
Brian Letzen ◽  
Clinton J. Wang ◽  
Julius Chapiro

Sign in / Sign up

Export Citation Format

Share Document